{
    "clinical_study": {
        "@rank": "1701", 
        "brief_summary": {
            "textblock": "To evaluate the virologic effect of combined administration of zidovudine and ddI or ddC. To\n      evaluate the immunologic effects of zidovudine and ddI or ddC. To evaluate combined\n      administration of zidovudine and ddI or ddC for clinical efficacy. To evaluate the safety\n      and the tolerance of the coadministration of zidovudine and ddI or ddC."
        }, 
        "brief_title": "The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Patients with PCP may be randomized to study medication after contacting the sponsor\n             and following a minimum 7-day course of therapy resulting in stabilization of their\n             disease. Patients with stabilized disease must have fever < 39 C for at least 48\n             hours, p02 (on room air) > or = 60 mm and an A/A gradient < or = 30 mm.\n\n          -  Prophylaxis for PCP.\n\n        Patients must have the following:\n\n          -  HIV-1 seropositive by any federally licensed ELISA.\n\n          -  Willingness to give informed consent.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Any immediately life-threatening infection or medical  condition present at time of\n             study entry.\n\n          -  Any active opportunistic infection requiring chronic therapy with any of the agents\n             listed in the exclusion concurrent medication section.\n\n          -  Neoplasms other than basal cell carcinoma or in situ carcinoma of the cervix.\n\n          -  Kaposi's sarcoma with visceral involvement or requiring systemic cytotoxic\n             chemotherapy.\n\n          -  AIDS dementia complex, > or = Stage 2.\n\n          -  History of zidovudine induced toxicity.\n\n          -  Prior history of acute pancreatitis during the past two years or chronic\n             pancreatitis.\n\n          -  Grade 2 neuropathy.\n\n          -  Intractable diarrhea.\n\n          -  History of seizures within the past six months or current requirement of\n             anticonvulsants.\n\n          -  Past or current heart disease.\n\n          -  Fever > 39 C at entry.\n\n        Concurrent Medication:\n\n        Current requirement of anticonvulsants.\n\n          -  Excluded:\n\n          -  It is intended that patients developing new opportunistic infections during the\n             course of the study will continue study participation, unless required therapy is\n             associated with significant neurologic or hematologic toxicities, in which case the\n             study medication may be temporarily discontinued.\n\n          -  Ganciclovir.\n\n          -  Chloramphenicol.\n\n          -  Cisplatinum.\n\n          -  Iodoquinol.\n\n          -  Systemic Pentamidine.\n\n          -  Disulfiram.\n\n          -  Ethionamide.\n\n          -  Glutethimide.\n\n          -  Gold.\n\n          -  Hydralazine.\n\n          -  Metronidazole.\n\n          -  Sodium Cyanate.\n\n          -  Thalidomide.\n\n          -  Vincristine.\n\n          -  Allopurinol.\n\n          -  Probenecid.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation therapy. (with the exception of electron beam therapy to an area of <\n             100cm/m2.)\n\n        Patients with the following are excluded:\n\n          -  Any immediately life-threatening infection or medical  condition present at time of\n             study entry.\n\n          -  Any active opportunistic infection requiring chronic  therapy with any of the agents\n             listed in the exclusion   concurrent medication section.\n\n          -  Active alcohol or drug abuse, sufficient in the investigator's opinion to prevent\n             compliance with study therapy.\n\n          -  Neoplasms other than basal cell carcinoma or in situ carcinoma of the cervix.\n\n          -  Kaposi's syndrome with visceral involvement or requiring systemic cytotoxic\n             chemotherapy.\n\n          -  AIDS dementia complex, > or = Stage 2.\n\n          -  History of zidovudine induced toxicity.\n\n          -  Any experimental therapy within 30 days.\n\n          -  Prior history of acute pancreatitis during the past two years or chronic\n             pancreatitis.\n\n          -  Grade 2 neuropathy.\n\n          -  Intractable diarrhea.\n\n          -  History of seizures within the past six months or current requirement of\n             anticonvulsants.\n\n          -  History of past or current heart disease.\n\n          -  Fever > 39 C at entry.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Any anti-HIV therapy (other than zidovudine), biologic response modifiers, or\n             pharmacologic doses of corticosteroids within eight weeks of entry (except for the\n             management of severe PCP, in which case duration is not to exceed 21 days).\n\n          -  Zidovudine therapy for greater than four weeks or prior discontinuation due to drug\n             toxicity.\n\n          -  Prior therapy with ddI, ddC, D4T, or interferon.\n\n          -  Any experimental therapy within 30 days.\n\n          -  Therapy within 30 days with neurotoxic drugs.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Radiation therapy within two weeks of entry or likely to require radiation therapy\n             (with the exception of electron beam therapy to an area of < 100cm/m2).\n\n        Active alcohol or drug abuse, sufficient in the investigator's opinion, to prevent\n        compliance with study therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002001", 
            "org_study_id": "052B", 
            "secondary_id": "02"
        }, 
        "intervention": [
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zalcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Zalcitabine", 
                "Didanosine", 
                "Zidovudine"
            ]
        }, 
        "keyword": [
            "Zalcitabine", 
            "Didanosine", 
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "Univ of Colorado Health Sciences Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }, 
                    "name": "Georgetown Univ Med Ctr / Main Hosp 4"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Darlinghurst", 
                        "country": "Australia"
                    }, 
                    "name": "Saint Vincent's Hosp Med Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "009275800"
                    }, 
                    "name": "San Juan Veterans Administration Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Puerto Rico"
            ]
        }, 
        "official_title": "The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "8709213", 
            "citation": "Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group. J Virol. 1996 Sep;70(9):5922-9."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002001"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 1991"
    }, 
    "geocoordinates": {
        "Georgetown Univ Med Ctr / Main Hosp 4": "38.895 -77.036", 
        "Saint Vincent's Hosp Med Centre": "-33.881 151.219", 
        "San Juan Veterans Administration Med Ctr": "18.466 -66.106", 
        "Univ of Colorado Health Sciences Ctr": "39.739 -104.985", 
        "Vanderbilt School of Medicine": "36.166 -86.784"
    }
}